Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at email@example.com.
Articles by Eric Palmer
Pfizer and Allergan are reportedly close to announcing a merger that would turn the two into the largest of the Big Pharma companies, Bloomberg has reported. They also would have the largest manufacturing network with possibly more than 100 production facilities. But Pfizer's acquisition record suggests that number would shrink significantly postmerger as it looked for ways to cut costs to pay for the massive deal.
While next week's long Thanksgiving holiday will be enjoyed by most workers in the U.S., logistics security firm FreightWatch International reminds companies that thieves use the added time to target warehouses and over-the-road trucks.
Connecticut-based Breckenridge Pharmaceutical is recalling a lot of duloxetine after a single tablet of a stomach-upset drug was found in a bottle of the generic anxiety drug.
Last month, four U.S. senators asked the FTC to investigate "possible illegal collusion" by saline solution manufacturers to determine whether they had been unfairly cashing in on a two-year shortage. But saline is only one of hundreds of hospital generic injectable drugs whose prices have soared in the last 8 years, And given the current state of affairs in the business, it is a situation unlikely to change.
Germany's Merck KGaA has for some years been taking steps to cash in on the growing population in emerging markets of people needing treatment for diabetes and associated conditions, sometimes building plants to make its diabetes treatments locally. Working through a joint venture, a plant is starting production in North Africa.
Just over a year ago, a Hikma sterile injectables plant in Portugal was grilled in a warning letter for a variety of failings, some that the FDA said it had been warned about before. But Jordan-based Hikma said today that the FDA has indicated those problems are behind it.
The hemophilia A treatment Advate is the cornerstone to the future of Baxalta, the company that was created when Baxter International spun off its drug operations in July. Now the newbie will be able to produce more of the product at a plant in Singapore it opened just last year.
Add to Valeant Pharmaceuticals' growing list of problems a manufacturing mess-up that is leading to a recall of a cholesterol fighter.
Novartis India Managing Director Ranjit Shahani told India's PTI that the drugmaker expects upgrades at two Sandoz plants that were issued a warning letter by the FDA to soon be back to full production.
Catalent, at the request of France's top pharma regulator, ANSM, halted production at a softgel plant on Friday after it reported to them that it had twice found "out-of-place" capsules in batches and suspected tampering.